Next Steps: With LDT Final Rule Now Null, Industry Groups Urge Lab Managers and Pathologists to Advocate for Change
CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight
CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight
Legal team’s bid to dismiss part of CMS inspector’s testimony as hearsay is denied by the Northern District of California federal court.
Of this month’s four Labs in Court cases, three involved kickbacks resulting in widely varying penalties.
In this month’s key cases, Myriad Genetics shells out, Illumina wins a decisive victory, a whistleblower suit is tossed, and false billing of UDTs costs a lab at least $11.6 million.